Episode Details
Back to EpisodesMonster Beverage (MNST): Sales +20.2% - But Every Case Sold For LESS
Published 2 weeks, 4 days ago
Description
Monster Beverage Corporation (MNST) Q2 2026 — Net sales $2,537.5M, +20.2%, vs a ~$2.43B bar. Adjusted EPS $0.60 vs $0.58 (GAAP $0.59) - a beat on BOTH bases. Adjusted operating margin 29.5% vs 31.3%. Case volume +22.3%, FASTER than revenue. AMC print, so the $94.16 close is PRE-print. A 2-for-1 split lands after the close Aug 10.
Monster beat, and we still rate it HOLD. The fact nobody put on screen: Monster shipped 304.9 million cases, up 22.3%, FASTER than the 20.2% of revenue. Strip the currency and the average case sold for $8.04 against $8.29 - every case went out 3.0% CHEAPER.
THE CALL: HOLD (4/5, A WONDERFUL BUSINESS, AND THE PRICE ALREADY KNOWS IT) — base-case value ~$86.0 vs ~$94.16 today.
KEY METRICS:
- CALL: HOLD 4/5, base case fair value ~$86 vs the $94.16 pre-print close (-9%). Bull $111, base $86, bear $42. Street: 44 analysts, 23 Buy / 18 Hold / 3 Sell, consensus Buy, $97.27 average target (low $88, high $105) - only +3% of upside. Our $86 is BELOW the Street's LOWEST published target, so on the tracked panel we are the single most cautious view. We are more CAUTIOUS and we DIFFER on the word.
- THE PRINT: net sales $2,537,473K vs $2,111,593K (+20.2%); FX added $48,539K so FX-neutral was +17.9%. Gross profit $1,419,634K, GM 55.9% vs 55.7%. Operating income $740,442K (+17.2%); ADJUSTED operating income $748,086K (+13.3%). Net income $584,540K (+19.6%). Diluted EPS $0.59 vs $0.50; adjusted $0.60 vs a $0.58 bar. Tax rate 23.9%. Diluted WASO 988,479K. H1 net sales $4,890,764K (+23.3%), H1 EPS $1.17.
- VOLUME DID EVERYTHING, PRICE WENT BACKWARDS: energy drink case sales 304,944K vs 249,336K 192oz case equivalents = +22.3%, FASTER than the 20.2% headline. Average net sales per case $8.20 vs $8.29 (-1.1%). Strip FX and the energy portfolio grew 18.6% on 22.3% more volume, so the FX-neutral price per case was $8.04 vs $8.29 - DOWN 3.0%. Monster cut realised price and bought volume while the rest of staples priced.
- THE GEOGRAPHY IS THE STORY: international net sales $1,163.1M vs $864.2M (+34.6%, FX-neutral +29.0%), now 46% of the company vs 41% - that is 70% of the entire $425.9M revenue increase. Implied US net sales +10.2%. Segments: Monster Energy Drinks $2,356.1M (+21.6%), Strategic Brands $143.7M (+10.6%), Alcohol $32.2M (-15.2%), Other $5.4M (-15.3%).
- THE GROWTH IS BEING BOUGHT: adjusted operating expenses +31.1% against net sales +20.2%. Distribution $118.8M = 4.7% of sales vs $82.0M = 3.9% (+45.1%). Selling $269.2M = 10.6% vs $196.9M = 9.3% (+36.7%). G&A $291.2M = 11.5% vs 12.6% (110bps of real leverage). SBC $35.7M vs $33.2M. Gross profit rose $243.2M, opex rose $134.4M - 55 cents of every extra gross profit dollar went straight back out.
- THE SCANNER EXHIBIT (EX-99.2, NielsenIQ, US convenience & gas, 4wks to 7/25/26): category +5.0%. MONSTER brand 29.4 share, UP 1.1 points, sales +9.1%. RED BULL 35.1 share, DOWN 1.5 points, +0.9%. CELSIUS 7.1 share, DOWN 0.9 points, sales -7.2%. ALANI NU 5.1 share, UP 2.0 points, +74.2%. But Monster Energy Company's TOTAL share fell 0.1 to 35.4: Reign -28.0%, Bang -19.1%, Java/coffee-energy -2.4%.
- CASH, BUYBACK, VALUATION: cash + investments $4,200.6M (up $948M in six months) with ZERO debt. ZERO shares repurchased in Q2; ~$900.0M of authorisation unused - from a team that spent $3,772M on buybacks in 2024. At $94.16: market cap $92,229M on 979,490K shares, EV $88,028M = 9.6x TTM revenue $9,219M and 41.4x TTM owner cash flow $2,128M, a 2.4% yield. Owner-earnings DCF (7.9% discount, 3.3% terminal, 24% FCF margin) = ~$86/share.
What to watch: UP: adjusted opex growing SLOWER than net sales for two straight quarters, price per case turning positive FX-neutral, or the buyback restarting. BEAR: margin down another 100bps, or Alani Nu past a 7 share. Next read: Q3 2026, November.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.